S11 Ep3: Garcia-Manero on MDS Treatment Updates With Luspatercept and Beyond
Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.
15m Aug 19, 2024
15m
S11 Ep3: FDA Approval Insights: Durvalumab/Chemotherapy in dMMR Advanced Endometrial Cancer
Dr Westin discusses the FDA approval of durvalumab plus chemotherapy for patients with dMMR advanced or recurrent endometrial cancer.
9m Aug 15, 2024
9m
S11 Ep2: ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma
Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.
10m Aug 12, 2024
10m
S11 Ep1: Rotow Reviews Key Updates on the Management of CNS Metastases in NSCLC
Dr Rotow discusses data that demonstrated the central nervous system activity of datopotamab deruxtecan and osimertinib in patients with NSCLC.
10m Aug 08, 2024
10m
S10 Ep50: Park and Grivas Expand on Treatment Updates in Bladder Cancer
Drs Park and Grivas discuss bladder cancer treatment updates, including results from the SunRISe-1 trial of TAR-200 plus cetrelimab in NMIBC.
16m Aug 07, 2024
16m
S10 Ep49: Halmos on the AE Profiles of Dato-DXd and Other ADCs in NSCLC
Dr Halmos discusses common AEs associated with the ADCs that are used in NSCLC and ways to manage and mitigate these toxicities.
10m Aug 05, 2024
10m
S10 Ep48: Lisberg Lends Insight About the TROPION-Lung01 Trial of Dato-DXd in NSCLC
Dr Lisberg discusses key findings from the TROPION-Lung01 trial of Dato-DXd in patients with previously treated advanced or metastatic NSCLC.
13m Aug 01, 2024
13m
S10 Ep47: Pegram Details the Use of Oral SERDs in ESR1+ Metastatic Breast Cancer
11m Jul 29, 2024
11m
S10 Ep47: Miller Discusses the Use of Selinexor in TP53 Wild-Type Advanced Endometrial Cancer
Dr Miller discusses findings from the SIENDO trial of selinexor maintenance therapy in patients with TP53 wild-type advanced endometrial cancer.
11m Jul 25, 2024
11m
S10 Ep46: Park and Sonpavde on Sacituzumab Govitecan Plus Enfortumab Vedotin in Metastatic Urothelial Cancer
Drs Park and Sonpavde discuss findings from the phase 1 DAD trial, as well as a schema for the frontline management of metastatic urothelial carcinoma. 
22m Jul 24, 2024
22m
S10 Ep45: Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa
Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.
17m Jul 18, 2024
17m
S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer
Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.
11m Jul 15, 2024
11m
S10 Ep43: Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma
Dr Orlowski discusses key efficacy data from the IMROZ trial of Isa-VRd in newly diagnosed, transplant-ineligible multiple myeloma.
10m Jul 11, 2024
10m
S10 Ep42: Park and Sonpavde on Nivolumab Plus Gemcitabine/Cisplatin in Cisplatin-Eligible Urothelial Cancer
Drs Park and Sonpavde discuss the CheckMate901 trial, which showed survival improvements with nivolumab plus chemotherapy in metastatic urothelial cancer.
8m Jul 10, 2024
8m
S10 Ep41: ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer
OncLive On Air partners with Two Onc Docs to bring insights on the ADRIATIC trial, data from which were presented at the 2024 ASCO Annual Meeting.
12m Jul 08, 2024
12m
S10 Ep40: FDA Approval Insights: Imetelstat in Lower-Risk MDS and Transfusion-Dependent Anemia
Dr Sekeres discusses the significance of the FDA approval of imetelstat for patients with lower-risk MDS and transfusion-dependent anemia.
8m Jul 01, 2024
8m
S10 Ep39: Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing
Drs Dietrich and Shiller detail the importance of collaboration between medical oncologists and pathologists to ensure beneficial oncology reflex testing.
19m Jun 27, 2024
19m
S10 Ep38: Agulnik Highlights Key Updates in GIST Research and Management
Dr Agulnik spotlights key updates from across the GIST landscape ahead of GIST Awareness Day on July 13.
16m Jun 24, 2024
16m
S10 Ep37: Reckamp Discusses the Integration of Pragmatic Elements Into Oncology Clinical Trial Designs
Dr Reckamp discusses the definition of pragmatic clinical trials and ways that clinical trial investigators can make their research more pragmatic.
10m Jun 20, 2024
10m
S10 Ep36: Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal Carcinoma
Dr Rosenberg discusses current standard strategies for treating patients with nasopharyngeal cancer, the evolving role of toripalimab in this treatment paradigm, and how future advances in nasopharyngeal cancer management may impact the head and neck cancer treatment paradigm more broadly.
17m Jun 17, 2024
17m
S10 Ep35: ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC
OncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting.
12m Jun 10, 2024
12m
S10 Ep35: Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations
Dr Paik discusses key findings from the phase 2 VISION trial investigating frontline tepotinib in patients with NSCLC harboring MET exon 14 skipping alterations, real-world data from the TOGETHER pooled analysis of tepotinib vs other frontline treatment options in this patient population, and insights regarding treatment sequencing with tepotinib in pretreated patients in this population.
14m Jun 06, 2024
14m
S10 Ep34: Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC
Lenz discusses the link between HER2 expression and responses with mCRC treatment regimens and how HER2 expression can guide treatment decision-making.
14m Jun 03, 2024
14m
S10 Ep33: Levy Lends Insights Into the Current and Future Use of ADCs in NSCLC
Dr Levy discusses the indication for trastuzumab deruxtecan in HER2+ NSCLC, other ADCs in development, and where the future of ADCs in NSCLC is headed.
10m May 30, 2024
10m
S10 Ep33: Park and Sonpavde on Considerations for Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer
Drs Park and Sonpavde emphasize their insights on the topline data from the EV-302 trial, considerations for community oncologists when deciding whether to prescribe enfortumab vedotin plus pembrolizumab to patients with urothelial carcinoma, their advice for monitoring and managing treatment-related toxicities with this combination, and more.
10m May 30, 2024
10m
S10 Ep32: Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Experts from across oncology specialties discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ASCO Annual Meeting.
17m May 23, 2024
17m
S10 Ep31: Ganjoo Discusses Treatment Plans, Patient Conversations, and the Role of Nab-Sirolimus in Malignant PEComa
Dr Ganjoo discusses unmet needs for patients with malignant PEComa, treatment plan considerations, and the use of nab-sirolimus in this disease.
12m May 20, 2024
12m
S10 Ep30: Brown Highlights the Rationale for the RAMP-301 Trial in Low-Grade Serous Ovarian Cancer
Dr Brown discusses the rationale for the RAMP-301 trial of avutometinib plus defactinib in low-grade serous ovarian cancer.
8m May 13, 2024
8m
S10 Ep30: Kummar on the Investigation of Rezatapopt in TP53 Y220C–Mutated Advanced Solid Tumors
Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.
13m May 09, 2024
13m
S10 Ep30: Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma
Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.
17m May 06, 2024
17m
S10 Ep29: Merkow and Connell Highlight Considerations for HAI Pump Use in CRC
Drs Merkow and Connell discuss reasons why they adopted HAI therapy as a treatment offering for patients with CRC, characteristics of patients who are good candidates for this treatment, and more.
24m May 02, 2024
24m
S10 Ep28: Bou Farhat and Nassar on the Use of NGS Mutation Signature vs IHC for Identifying dMMR Tumors
Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.
25m Apr 29, 2024
25m
S10 Ep27: FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
Dr Usmani details the FDA approval of cilta-cel for patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy.
9m Apr 22, 2024
9m
S10 Ep26: Lunning and Rutherford Detail Considerations for BV-AVD Use in Older Patients With Hodgkin Lymphoma
Drs Lunning and Rutherford discuss findings from the ECHELON-1 trial of BV-AVD in the cohort of patients with Hodgkin lymphoma over 60 years of age.
14m Apr 18, 2024
14m
S10 Ep25: Breast Cancer Experts Share Obstacles and Successes as Women in Oncology
Drs Graff, Mahtani, McCann, and Rugo shared moments throughout their lives and careers that sparked their interest in oncology, setbacks they overcame when building their careers, obstacles they encounter as women in the field, and ways that gender bias can be confronted at both the individual and institutional levels.
42m Apr 11, 2024
42m
S1 Ep18: FDA Approval Insights: Ponatinib in Ph+ ALL
Dr Jabbour expands on the multiple milestones achieved through ponatinib’s FDA approval for patients with Ph-positive ALL; the agent’s potency and unique mechanism of action; and key efficacy and safety data from the PhALLCON trial supporting this regulatory decision.
9m Apr 08, 2024
9m
S10 Ep24: Schmid Summarizes Updates in HER2-Positive Breast Cancer Management
Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.
14m Apr 01, 2024
14m
S10 Ep23: Wagner on the Investigation of Nab-Sirolimus in Advanced Malignant PEComa
Dr Wagner discusses current unmet needs for patients with PEComa, how ongoing research aims to address some of these gaps, and how findings from the AMPECT trial in particular support the use of nab-sirolimus in patients with advanced malignant disease.
15m Mar 28, 2024
15m
S10 Ep22: CRC Experts Highlight AE Management and Prevention Strategies for TAS-102/Bevacizumab, Regorafenib, and Fruquintinib
Strickler, Leung, Dasari, and O'Neill discuss adverse effect monitoring and management with standard agents for patients with colorectal cancer.
35m Mar 25, 2024
35m
S10 Ep21: Bagley Summarizes the ACTION trial of ONC201 in H3 K27M–Mutant Diffuse Midline Gliomas
Dr Bagley discusses the evaluation of the small molecule ONC201 in the phase 3 ACTION trial in H3 K27M–mutant diffuse midline gliomas.
14m Mar 21, 2024
14m
S10 Ep20: Lunning and Herrera Highlight Frontline Hodgkin Lymphoma Management Strategies
Dr Lunning sits down with Alex Herrera, MD, of City of Hope, to discuss the frontline management of Hodgkin lymphoma, including the rationale for the SWOG 1826 trial, the collaborative efforts between pediatric and adult oncologists that led to the successful initiation of this trial, potential future directions for this research, and more.
14m Mar 18, 2024
14m
S10 Ep19: FDA Approval Insights: NALIRIFOX in Metastatic Pancreatic Cancer
Dr Wainberg discusses the FDA approval of first-line NALIRIFOX for patients with metastatic pancreatic adenocarcinoma, key data from NAPOLI 3, and the potential evolution of NALIRIFOX’s role in the treatment of patients with pancreatic cancer.
7m Mar 11, 2024
7m
S10 Ep18: Dr Kyriakopoulos on the Investigation of Masofaniten Plus Enzalutamide in mCRPC
Dr Kyriakopoulos sheds light on the potential synergy and pharmacokinetic interactions between masofaniten and enzalutamide when used in combination for patients with prostate cancer; contextualizes safety and pharmacokinetic findings from the phase 1 portion of a phase 1/2 study; and outlines key objectives of the agent’s ongoing evaluation in the phase 2 portion of the study.
11m Mar 07, 2024
11m
S10 Ep17: Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice
Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma, his anticipated use of the agent since its inclusion on UCSF’s formulary, and the debate around Epstein-Barr virus as a selection criteria for treatment eligibility.
9m Feb 29, 2024
9m
S10 Ep16: Mims Expands on the Evaluation of Emavusertib in the TakeAim Leukemia Trial of AML and MDS
Dr Mims discusses the utility of emavusertib in acute myeloid leukemia and myelodysplastic syndrome and the rationale for the TakeAim Leukemia trial.
10m Feb 26, 2024
10m
S10 Ep15: Tripathy Talks Through the Enduring Impact of the Miami Breast Cancer Conference
Dr Tripathy discusses aspects of the Miami Breast Cancer Conference that stood out to him during his first time speaking at the meeting, ways that Miami Breast has evolved over the years, and the types of valuable multidisciplinary discussions that the meeting inspires.
16m Feb 22, 2024
16m
S10 Ep14: Kitco and Patel Emphasize the Importance of GVHD Research and Awareness
Drs Kitko and Patel discuss graft-versus-host disease recognition, treatment selection, and ongoing research with novel agents and biomarkers of response.
16m Feb 19, 2024
16m
S10 Ep13: FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced/Metastatic Urothelial Carcinoma
Dr Galsky discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced or metastatic urothelial cancer, key efficacy and safety data from the EV-302 trial, and future directions in urothelial cancer research.
9m Feb 12, 2024
9m
S10 Ep12: Community Oncologists on the Importance of Self-Reliance and Collegial Trust as Women in Medicine
Drs Jacob, Van Der Wall, and Wright-Browne discuss challenges related to gender bias that they have faced throughout their careers, growth opportunities that have arisen from these obstacles, and the importance of reflecting on past accomplishments and future goals.
22m Feb 08, 2024
22m
S10 Ep11: Lunning and Brander Emphasize the Importance of Early CLL Diagnosis and Treatment
Drs Lunning and Brander discuss the evolution of chronic lymphocytic leukemia management.
14m Feb 05, 2024
14m